High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 1012-1017

  Su, Shih Hann ^a,b   Martel Laferrière, Valérie ^b   Labbé, Annie Claude ^b,c   Snydman, David R ^a   Kent, David ^a   Laverdière, Michel ^b,c   Béliveau, Claire ^b,c   Logvinenko, Tanya ^a   Cohen, Sandra ^b,c   Lachance, Silvy ^b,c   Kiss, Thomas ^b,c   Roy, Jean ^b,c  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Antiviral prophylaxis; Mini allogeneic; Shingles; Varicella zoster; VZV virus

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DERMATOME; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; POSTHERPETIC NEURALGIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; VIRUS ACTIVATION;

EID: 79958713331     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.025     Document Type: Article

References (37)

1. Donahue J.G., Choo P.W., Manson J.E., et al. The incidence of herpes zoster. Arch Intern Med 1995, 155:1605-1609.
2. Locksley R.M., Flournoy N., Sullivan K.M., et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985, 152:1172-1181.
3. Han C.S., Miller W., Haake R., et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994, 13:277-283.
4. Koc Y., Miller K.B., Schenkein D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000, 6:44-49.
5. Styczynski J., Reusser P., Einsele H., et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009, 43:757-770.
6. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:471-482.
7. Boeckh M., Kim H.W., Flowers M.E., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a randomized double-blind placebo-controlled study. Blood 2006, 107:1800-1805.
8. Ljungman P., Wilczek H., Gahrton G., et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986, 1:185-192.
9. Perren T.J., Powles R.L., Easton D., et al. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988, 85:99-101.
10. Gratwohl A., Baldomero H., Passweg J., et al. Increasing use of reduced-intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 2002, 30:813-831.
11. Gratwohl A., Baldomero H., Schwendener A., et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009, 43:275-291.
12. Schulenburg A., Fischer M., Kalhs P., et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leuk Lymphoma 2005, 46:1755-1760.
13. Bachanova V., Brunstein C.G., Burns L.J., et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009, 43:237-244.
14. Meijer E., Dekker A.W., Lokhorst H.M., et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004, 6:171-178.
15. Labbe A.C., Su S.H., Laverdiere M., et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007, 13:1192-1200.
16. Sabry W., Le Blanc R., Labbe A.C., et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009, 15:919-929.
17. Higman M.A., Vogelsang G.B. Chronic graft-versus-host disease. Br J Haematol 2004, 125:435-454.
18. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
20. Wade J.C., Newton B., Flournoy N., et al. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984, 100:823-828.
21. Engels E.A., Rosenberg P.S., Biggar R.J. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study; Multicenter Hemophilia Cohort Study. J Infect Dis 1999, 180:1784-1789.
22. Glesby M.J., Moore R.D., Chaisson R.E. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:370-375.
23. Veenstra J., Krol A., van Praag R.M., et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995, 9:1153-1158.
24. Gourishankar S., McDermid J.C., Jhangri G.S., et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004, 4:108-115.
25. Whitley R.J., Gnann J.W. Herpes zoster in the age of focused immunosuppressive therapy. JAMA 2009, 301:774-775.
26. Busca A., Locatelli F., Barbui A., et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003, 5:132-139.
27. Frere P., Baron F., Bonnet C., et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006, 37:411-418.
28. Schuchter L.M., Wingard J.R., Piantadosi S., et al. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989, 74:1424-1427.
29. Kim D.H., Messner H., Minden M., et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008, 10:90-98.
30. Carella A.M., Champlin R., Slavin S., et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000, 25:345-350.
31. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-S26.
32. Sandmaier B.M., Mackinnon S., Childs R.W. Reduced-intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2007, 13:87-97.
33. Asano-Mori Y., Kanda Y., Oshima K., et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008, 83:472-476.
34. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007, 110:3071-3077.
35. Thomson K.J., Hart D.P., Banerjee L., et al. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:1065-1069.
36. Klein A., Miller K.B., Sprague K., et al. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplant April 2010, (Epub ahead of print).
37. Hata A., Asanuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic cell transplants. N Engl J Med 2002, 347:26-34.